Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131890 | 0.83 | P2RX7 (0.50) | P2RX7EPHX2HDAC6MEN1KMT2A | |
| SCHEMBL10067533 | 0.81 | P2RX7 (0.67) | P2RX7EPHX2HDAC6MEN1KMT2A | |
| SCHEMBL9949022 | 0.78 | P2RX7 (0.48) | P2RX7EPHX2MEN1KMT2A | |
| SCHEMBL9949019 | 0.75 | HDAC6 (0.48) | P2RX7EPHX2HDAC6MEN1KMT2A | |
| SCHEMBL1160892 | 0.74 | P2RX7 (0.55) | P2RX7EPHX2HDAC6MEN1KMT2A | |
| SCHEMBL9948611 | 0.73 | HSD11B1 (0.49) | EPHX2HSD11B1 | |
| SCHEMBL1846513 | 0.72 | GRIN2D (0.48) | EPHX2HSD11B1 | |
| SCHEMBL1846514 | 0.72 | GRIN2D (0.48) | EPHX2HSD11B1 | |
| SCHEMBL9948664 | 0.72 | GRIN2D (0.48) | EPHX2HSD11B1 | |
| SCHEMBL1846516 | 0.72 | GRIN2D (0.48) | EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536173-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | SANOFI (FR) | 2013-09-17 | — | — | US | disclosed |
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NR2C2, CBR3, NR0B2 | P2RX7 756/4885EPHX2 2241/4885HDAC6 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.